Gene Location [1]
Cell cycle control
Variant Type

CCND2 Amplification is present in 0.89% of AACR GENIE cases, with colon adenocarcinoma, testicular mixed germ cell tumor, breast invasive ductal carcinoma, rectal adenocarcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence [4].

Top Disease Cases with CCND2 Amplification

Significance of CCND2 Amplification in Diseases

Malignant Solid Tumor +

Malignant Glioma +

Non-Hodgkin Lymphoma +

Germ Cell Tumor +

Colorectal Carcinoma +

Squamous Cell Lung Carcinoma +

Esophageal Carcinoma +

Soft Tissue Sarcoma +

Breast Carcinoma +

Osteosarcoma +

Chondrosarcoma +

Dedifferentiated Chondrosarcoma +

Gastric Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Meningioma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.